Grant/RFP Opportunities

UCB, Inc. Medical Affairs Request for Proposal (RFP)

Deadline Date: July 18, 2014
RFP Number: UCB.EarlyCD2014
Area of Interest: Crohn’s Disease
Purpose of Request for Proposal (RFP): UCB, Inc. is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. Crohn’s disease (CD) is a chronic, inflammatory disease of the gastrointestinal tract, most common in the ileum and/or colon. About 300,000-500,000 Americans have moderate-to-severe CD. There are substantial impacts on the quality of life, work productivity, and lost work in patients with CD. —DOWNLOAD THE RFP

Genentech Call for Grant Notification
Deadline: May 30, 2014

http://www.gene.com/assets/frontend/pdf/content/good/grants-giving/genentech-cgn-for-quality-of-care-research-projects-march-2014.pdf

Genentech is seeking to support up to 3-4 research projects that use already established modern electronic data capture methods to increase the quality of healthcare and improve our understanding of the value of patient engagement during the course of their treatment. Successful research proposals will use an established electronic capture method in an innovative setting to measure patient engagement, patient-reported symptoms, overall quality of care and other national quality strategy criteria. Research proposals should be designed to capture quantifiable data from core patient-reported outcome sets for patients in any one of Genentech’s therapeutic areas of interest. Ideally these data can then be incorporated into Electronic Medical Records. Innovative use of patient reported data and data analysis to identify gaps in treatment or improve on quality of care as it relates to the National Quality Strategy criteria for Patient and Family Engagement are highly encouraged.

 

Genzyme Request for Proposal Multiple Sclerosis

Deadline: June 8, 2014

 

You are invited to submit a grant proposal to address the educational need outlined in the attached document. Please review and return your completed proposal via the Genzyme U.S. Grant Website at www.genzyme.com by 5 p.m., EST on June 8, 2014. If a submission is not completed by this date, your proposal will not be accepted. When entering proposal into the website, please reference the following:

Tag ID: PL-4VXTM
Therapeutic Area: Multiple Sclerosis (MS)
Area of Interest: Women’s Health and MS


Please note than an applicant may be ineligible to receive a grant in response to this RFP if the applicant has performed any services under contract with Genzyme U.S. during the last 12 months in connection with:

• A consultant meeting; or
• An advisory board meeting

In the same therapeutic area as this request for proposal (“RFP”).

If the applicant has performed such services, please forward a copy of the contract immediately, prior to responding to the RFP, so that we can determine your eligibility. If not, please acknowledge this in your application writing.

Please note that you must select the type of activity that you are proposing, i.e., Live, Enduring or Live and Enduring.

Submission instructions are available on the website. If you have a question, please contact Victoria DeMoranville at victoria.demoranville@genzyme.com.


sanofi-aventis US Hypercholesterolemia RFP
Deadline: June 9, 2014 
View full RFP for details. 


sanofi-aventis US Hypercholesterolemia RFP
Deadline: June 16, 2014 
View full RFP for details.


sanofi-aventis US Diabetes RFP
Deadline: June 23, 2014
View full RFP for details.